Lewy body dementia (LBD) and Alzheimer’s disease are both progressive brain diseases that cause cognitive decline, but they differ in which symptoms appear first, how the disease behaves day to day, and how quickly it progresses. Alzheimer’s is far more common, affecting an estimated 7.1 million Americans, while LBD is the second most common form of dementia. The distinction matters because the two diseases respond differently to treatment, and medications that help one can be dangerous for the other.
What Happens in the Brain
The two diseases are driven by different toxic proteins building up in brain cells. In Alzheimer’s, the primary culprits are amyloid plaques that form between neurons and tangled fibers of tau protein inside them. In Lewy body dementia, the key protein is alpha-synuclein, which clumps into round deposits called Lewy bodies inside nerve cells. These deposits disrupt the brain’s chemical messengers, particularly dopamine, which controls movement, and acetylcholine, which supports memory and attention.
The picture gets complicated because the two diseases frequently overlap. Lewy body pathology shows up alongside Alzheimer’s pathology in roughly 30% of Alzheimer’s cases. This overlap is one reason LBD is so often misdiagnosed. When pathologists examine brain tissue, they look for distinct patterns of each protein to determine which disease was dominant, but in life, the mixed cases can be difficult to sort out.
How Early Symptoms Differ
Alzheimer’s almost always announces itself through memory loss. People struggle to learn and retain new information, forget recent conversations, and can’t improve their recall even when given hints or cues. Over time, a second area of thinking declines as well, usually language or the ability to plan and organize tasks.
LBD takes a different path. Memory problems can be present, but they’re usually not the most noticeable early symptom. Instead, people with LBD tend to have early trouble with attention, concentration, and visual-spatial skills, like judging distances or recognizing objects. They may struggle to stay focused on a task or follow a complex set of instructions well before they start forgetting names or appointments.
The most distinctive early feature of LBD is fluctuating cognition. A person may seem sharp and engaged one hour, then stare blankly into space or become drowsy and confused the next, despite having slept well. These swings can happen within a single day or shift from day to day. The unpredictability often confuses families, who may wonder if the person is faking or simply tired. Alzheimer’s causes a steadier, more gradual decline without these dramatic fluctuations.
Visual Hallucinations
Well-formed visual hallucinations, meaning vivid images of people, children, animals, or insects, are one of the hallmark features of LBD. They appear in roughly 60% to 85% of confirmed cases and tend to begin within the first five years after cognitive symptoms start. When hallucinations show up that early, the odds are four to five times greater that the underlying disease is LBD rather than Alzheimer’s.
Alzheimer’s patients can develop hallucinations too, but this typically happens later in the disease and occurs in a smaller proportion, roughly 11% to 38% of cases. The hallucinations in LBD are often strikingly detailed. People describe seeing strangers sitting in their living room or small animals crossing the floor. Early on, many patients recognize these visions aren’t real, though that awareness fades as the disease progresses.
Movement Problems
Parkinsonian motor symptoms are common in LBD and rare in early or mid-stage Alzheimer’s. People with LBD may develop a shuffling walk, stiff limbs, slower movements, a stooped posture, and reduced facial expression. In dementia with Lewy bodies (one of the two forms of LBD), these motor features typically appear within a year of cognitive symptoms.
Diminished facial expression is one of the earliest and most reliable motor signs distinguishing LBD from Alzheimer’s. People with Lewy body pathology are more than twice as likely to show reduced facial expressiveness compared to those with pure Alzheimer’s pathology. Speech changes, rigidity in the arms, and a slower overall movement speed also appear more frequently in LBD. While Alzheimer’s patients can develop some motor difficulties in late stages, these tend to be less specific and occur years into the disease.
Sleep Disruption as an Early Warning
A sleep disorder called REM sleep behavior disorder (RBD) is one of the most telling early signs of LBD, and it can begin years or even decades before any cognitive symptoms appear. Normally during REM sleep, your body is temporarily paralyzed so you don’t act out your dreams. In RBD, that paralysis fails. People kick, punch, shout, or leap out of bed while dreaming, sometimes injuring themselves or their bed partner.
RBD affects up to 76% of people with LBD and is now considered a core diagnostic feature. It is uncommon in Alzheimer’s, affecting less than 1% of the general population. In the rare cases where Alzheimer’s patients do develop RBD, brain examinations almost always find alpha-synuclein deposits alongside the Alzheimer’s pathology, suggesting Lewy body disease was quietly present too.
How Each Disease Is Diagnosed
Distinguishing the two diseases during life remains challenging, especially because symptoms overlap and mixed pathology is common. Doctors rely on the pattern and timing of symptoms: early memory loss points toward Alzheimer’s, while early fluctuations in alertness, visual hallucinations, movement problems, or RBD point toward LBD.
One imaging tool has proven particularly useful. A DaTscan uses a small amount of a radioactive tracer to visualize dopamine-producing areas in the brain. In LBD, dopamine activity is reduced because Lewy bodies damage those neurons. In pure Alzheimer’s, dopamine function is typically preserved. The scan has a sensitivity of 78% to 93% and a specificity of 84% to 92% for identifying LBD, making it one of the most reliable ways to tell the two diseases apart. It’s FDA-approved and available at most freestanding imaging centers in the U.S.
Medication Sensitivity in LBD
One of the most important practical differences between these diseases involves how patients react to certain medications. An estimated 80% of LBD patients experience hallucinations severe enough to need treatment, yet the drugs most commonly used for hallucinations and agitation, antipsychotics, can be dangerous for them. Between 30% and 50% of LBD patients have severe sensitivity reactions to even small doses of these medications, which can worsen confusion, rigidity, and movement problems and in some cases become life-threatening.
This sensitivity doesn’t occur in Alzheimer’s patients to the same degree, which is why an accurate diagnosis is so critical. If someone with undiagnosed LBD is treated as though they have Alzheimer’s and given a standard antipsychotic for behavioral symptoms, the consequences can be serious. Families and caregivers should make sure any treating physician knows about a confirmed or suspected LBD diagnosis before new medications are prescribed.
Life Expectancy and Disease Progression
LBD progresses faster than Alzheimer’s on average. A large retrospective study found that median survival from diagnosis was approximately 3.7 years for LBD compared to nearly 7 years for Alzheimer’s. After adjusting for age, sex, other health conditions, and medication use, the gap held steady: men with LBD survived a median of 3.3 years versus 6.7 years for men with Alzheimer’s, and women with LBD survived about 4.0 years versus 7.0 years for women with Alzheimer’s.
The shorter survival in LBD reflects the broader burden of the disease. Because it affects movement, cognition, sleep, and the autonomic nervous system (which controls blood pressure, digestion, and other automatic functions), people with LBD face complications on multiple fronts simultaneously. Falls, swallowing difficulties, and infections tend to occur earlier in the course of illness. Alzheimer’s progresses more slowly through its stages, though it too is ultimately fatal, with many patients living a decade or more from their first symptoms.